Diagnosis and Management of Homozygous Familial Hypercholesterolemia

1.50 CME
90 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Diagnosis and Management of Homozygous Familial Hypercholesterolemia

Overview


Release Date: November 30, 2023
Expiration Date: (12 months after release date): November 30, 2024


Program Description

Interact and learn alongside virtual patients and physicians as you practice managing children and adults with HoFH. This platform allows participants to work through real-life clinical scenarios in a stress-free environment with expert guidance and mentorship throughout each case scenario. Expert faculty will review the pathogenesis of HoFH, symptoms, diagnosis, guideline-based cascade screening, and the latest data for approved and evidence-based management for HoFH. An emphasis on strategies to individualize therapy depending on genetics and a patient's response to therapy is applied throughout the simulation to ensure patients are receiving the most appropriate management for their disease.


Intended Audience

This activity will target cardiologists, lipidologists, endocrinologists, internists, infusion center nurses, pediatricians and other healthcare providers who treat patients with FH, including HoFH.


Commercial Supporter

This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.


Educational Objectives

Upon completion of the educational activity, participants should be able to:

1.Implement strategies for the timely diagnosis of HoFH
2. Discuss the role of cascade screening in identifying patients with HoFH
3. Integrate current approved therapies for the treatment of HoFH
4. Individualize treatment for patients with HoFH based on response to therapy and/or disease genetics


Physician Continuing Education

In support of improving patient care, this activity has been planned and implemented by Horizon CME. Horizon CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation Statement

Horizon CME designates this enduring activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


Conflicts of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, Horizon CME must ensure balance, independence, objectivity, and scientific rigor. Prior to an activity, all faculty, authors, editors, and planning committee members participating in a Horizon CME activity are required to disclose to attendees any relevant financial interest or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Horizon CME has mitigated any conflicts of interest for this activity.


Disclosure of Unlabeled Use

Horizon CME requires that faculty participating in any continuing medical education (CME) to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Disclaimer

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.


Faculty

Moderator:
James A. Underberg, MD, MS, FACP, FNLA
Clinical Assistant Professor of Medicine
NYU Center for Prevention of Cardiovascular Disease
NYU School of Medicine
New York, NY

Faculty:
Julie Brothers, MD, FAAP
Medical Director, Lipid Heart Clinic
Co-Medical Director, Preventive Cardiovascular Program
Medical Director, Coronary Anomaly Management Program
Associate Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA


Faculty Disclosures

Julie Brothers, MD, FAAP, has served on an advisory board for Regeneron Pharmaceuticals.

James A. Underberg, MD, MS, FACP, FNLA, has served on a speakers bureau for Amarin, Amgen, Amryt and Regeneron as well as on an advisory board for Esperion, Merck, Novartis, Pfizer, and Precision Bio. He is also a consultant for Amgen and conduct research for Amryt.


Instructions to Recieve Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

1. Read the CME/CE information and faculty disclosures.
2. Participate in the online activity.
3. Complete the post-test.
4. Complete the evaluation form available. The last day to access the evaluation is November 30, 2024 at 11:59pm PST (Pacific Standard Time)

For CME questions please contact: admin@horizoncme.com

To receive CME/CE credits, participants must complete the pre and post assessment questions and the program evaluation. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved within your Dashboard or Transcript, which you can access at any time. For information about the accreditation of this program, please contact: admin@horizoncme.com.


James Underberg Faculty Headshot

James A. Underberg, MD, MS, FACP, FNLA

Dr. Underberg is a Clinical Lipidologist. He is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. His Undergraduate and Graduate degrees are from Yale University and his medical degree is from the University of Pennsylvania. His internship and residency was at NYU and Bellevue Hospitals in NYC. Dr. Underberg is the Director of the Bellevue Hospital Lipid Clinic. He holds joint appointments in the divisions of General Internal Medicine and Endocrinology at NYU.

Dr. Underberg is Master of the National Lipid Association, Past-President of the National Lipid Association, Past-President of the American Board of Clinical Lipidology & Current President of the Foundation of the National Lipid Association. He serves on the editorial board of the Journal of Clinical Lipidology and is a Section editor of Current Atherosclerosis Reports.

Dr. Underberg’s Clinical Interests focus on the clinical management of patients with lipids and lipoprotein disorders and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of Clinical Lipidology.

He sees patients both at Bellevue Hospital and in a private practice setting.

Dr. Julie A. Brothers
Julie Brothers, MD, FAAP

Julie Brothers, MD is the Medical Co-Director of the Preventive Cardiovascular Program and the Medical Director of the Lipid Heart Clinic at the Children’s Hospital of Philadelphia, a position she has held for over 15 years. She has served as Principal Investigator on several clinical trials in the pediatric dyslipidemia population and has published many manuscripts and book chapters on this topic. She is committed to promoting a heart healthy lifestyle in all children with lipid disorders.


Copyright Statement

This CME simulation activity is licensed to Horizon CME. Copyright © 2023 Syandus Inc and Horizon CME. All rights reserved. No part of this simulation activity may be reproduced without written permission from Horizon CME and Syandus Inc.